Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Erding – page 61

1 344 clinical trials in Erding, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Erding at a glance
1 344
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 344 trials in Erding

Open in trial search

Asthma

Not recruiting

Study on the Safety of CHF5993 Inhaler with HFA-152a vs. HFA-134a in Patients with Moderate to Severe Asthma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol
  • Sponsor:Chiesi Farmaceutici S.p.A.

Migraine

Not recruiting

Study on Botulinum Toxin Type A for Preventing Episodic Migraine in Adults

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Botulinum Toxin Type A - Haemagglutinin Complex
  • Sponsor:Ipsen Innovation

Migraine

Not recruiting

Study on Botulinum Toxin Type A for Preventing Chronic Migraine in Adults

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Botulinum Toxin Type A - Haemagglutinin Complex
  • Sponsor:Ipsen Innovation

Hidradenitis

Not recruiting

Study on the Effectiveness and Safety of SAR444656 for Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study of GLPG3667 for Adults with Active Systemic Lupus Erythematosus

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:GLPG3667 fumarate
  • Sponsor:Lakefront Biotherapeutics

Study of Pembrolizumab and Axitinib Combination Versus Sunitinib for Patients with Advanced or Metastatic Kidney Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Axitinib
  • Sponsor:Merck Sharp & Dohme LLC

Dermatitis atopic

Not recruiting

Study on SAR444656 for Adults with Moderate to Severe Atopic Dermatitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Systemic scleroderma

Not recruiting

Study on BI 685509 for Adults with Systemic Sclerosis to Assess Effects on Lung Function and Symptoms

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:BI 685509
  • Sponsor:Boehringer Ingelheim Espana S.A.

Parkinson's disease

Not recruiting

Study on the Long-Term Safety and Effectiveness of Minzasolmin and Iodine Ioflupane (123I) in Patients with Parkinson's Disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ioflupane (123I)
  • Sponsor:UCB Biopharma
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Botulinum Toxin Type A
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study of Vobramitamab Duocarmazine and Prednisone for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Macrogenics Inc.

Study on the Effectiveness and Safety of Deucravacitinib for Patients with Active Systemic Lupus Erythematosus (SLE)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Erding

What the registry says about research in the country

01 Hematologic Disorders

Innovative research focusing on Myelodysplastic Syndrome (MDS), comparing novel therapeutic approaches for patients with lower-risk conditions. The studies aim to evaluate treatment effectiveness in managing blood cell production disorders.

  • Lower-risk MDS management
  • Blood cell production therapy
  • Treatment conversion studies

Current trials are investigating comparative effectiveness of different therapeutic agents in managing transfusion dependency.

02 Blood Disorders

Advanced research into polycythemia vera treatment resistance, utilizing artificial intelligence to predict treatment outcomes. Studies focus on understanding hydroxyurea resistance patterns in affected patients.

  • Treatment resistance evaluation
  • AI-driven predictions
  • Therapeutic monitoring

Research combines traditional clinical approaches with modern machine learning techniques to optimize treatment strategies.

03 Cardiovascular Medicine

Groundbreaking research on acute coronary syndrome and atrial fibrillation, exploring optimized antiplatelet therapy protocols. Studies evaluate new approaches for patients undergoing percutaneous coronary intervention.

  • Antiplatelet therapy optimization
  • Cardiac intervention outcomes
  • Bleeding risk management

Investigations focus on balancing therapeutic efficacy with safety in complex cardiac conditions.

04 Advanced Myelofibrosis

Clinical investigations of intermediate and high-risk myelofibrosis, exploring combination therapies and novel treatment approaches. Research aims to establish optimal dosing strategies for enhanced patient outcomes.

  • Combination therapy assessment
  • Treatment tolerability studies
  • Dose optimization research

Studies focus on developing safer and more effective treatment protocols for advanced stages of the disease.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.